$TRIL As more solid tumor data comes out for $ALXO, investors of $TRIL are salivating over the future potential for best in class assets. Keep in mind monotherapy for $TRIL for heme at higher dose for TTI-622 was better than combination therapy for Heme for competitors.
$TRIL keep in mind we still have not seen higher dose TTI-621 data, which was rewarded an oral presentation at ASH. The company has been very tight lipped on details of TTI-621 and is already planning multiple phase 2 studies for next year for both assets.
$ALXO will continue to make stupid comparisons about cetuximab and ALX148 synergy being superior to an insignificant dose of TTI-621 and cetuximab. $TRIL assets have superceded ALX148 on every other known comparison and have not hit MTD
You can follow @BioRampCapital.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled:
Those who think consciousness raising & movement building are disconnected, or even a distraction from electoral politics have not paid attention to the history of social change.In this thread, we
Read more
The 2020s will be known as the Remote Work decadeA few predictions of what is likely to emerge[ a thread ] Third Space: Office and Working from Home will
Read more
1/29: Have you ever had a concept explained to you that helps frame complex issues you’ve been wrestling with and opens your eyes to new possibilities? A concept that I
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.